

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2023



© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital 687 - 1081 Burrard Street Vancouver, BC V6Z 1Y6

Tel: 604.806.8515 Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677 St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222 Website: www.bccfe.ca Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

5.1 Drug Names and Definitions










1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

February 2023

N = 7534



Health Authority	Male	Female	All
FRASER	1510	468	1978
INTERIOR	444	122	566
NORTHERN	153	76	229
VANCOUVER COASTAL	3285	443	3728
VANCOUVER ISLAND	823	169	992
	6215	1278	7493
		Unknown/not stated:	41
		Total:	7534

Definitions:

On antiretroviral therapy defined as being on treatment in the current month Unknown/not stated defined as being on treatment in the current month, and city of residence unknown Male & Female refer to Sex at birth




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report



1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2018 - February 2023)

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



BRITISH COLUMBIA Ministry of Health

Monthly Report



1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2018 - February 2023)

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report





Ministry of Health






Monthly Report

in HIV/AIDS

How you want to be treated.

1.5 **BC-CfE Enrolment: New Antiretroviral Participants** (February 2018 - February 2023)



Monthly Report


CENTRE for **EXCELLENCE**

in HIV/AIDS

HEALTH CARE

How you want to be treated.






Ministry of Health

BRITISH COLUMBIA

Monthly Report



1.7 Percent Distribution of Inactive Participants by CD4 Count (February 2018 - February 2023)


BRITISH COLUMBIA CENTRE for EXCELLENCE





Monthly Report

1.8 Active and Inactive Participants (February 2018 - February 2023)






Monthly Report

in HIV/AIDS





Ministry of Health


BRITISH COLUMBIA

HEALTH CARE

How you want to be treated.

Monthly Report








Monthly Report

1.11 **Distribution of Participants on Nucleoside/Nucleotide Analogues** at the time of first start of ARV Therapy by INGREDIENT

(February 2018 - February 2023)

This document is best viewed in colour.

Drug definitions available in the back.



Ministry of Health

BRITISH COLUMBIA




HEALTH CARE

How you want to be treated.

Monthly Report






Monthly Report

in HIV/AIDS

How you want to be treated.

1.13 **Distribution of Participants on Protease Inhibitor** at the time of first start of ARV Therapy by INGREDIENT


(February 2018 - February 2023)



Monthly Report

in HIV/AIDS





BRITISH

COLUMBIA


How you want to be treated.

Monthly Report

in HIV/AIDS

Distribution of Participants on Non-Nucleosides 1.15 at the time of first start of ARV Therapy by INGREDIENT

(February 2018 - February 2023)




BRITISH COLUMBIA

How you want to be treated.

Monthly Report






Monthly Report

1.17 **Distribution of Participants on Entry/Integrase Inhibitors** at the time of first ARV Therapy by INGREDIENT

(February 2018 - February 2023)

This document is best viewed in colour.

Drug definitions available in the back.



Ministry of Health

BRITISH COLUMBIA




HEALTH CARE

How you want to be treated.

Monthly Report

1.18 Baseline CD4 for Antiretroviral First Starts (February 2018 - February 2023)







BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report






Monthly Report



1.20 Cumulative Resistance Testing Results by Resistance Category (February 2018 - February 2023)

Monthly Report







2.1 Duration of ARV treatment in the Province of BC, 1987-2023 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Curr (n)	rent CD4 Median		ent PVL Median	Current ARV Median
1987	31	4	0	4	1	1030	3	<40	4
1988	32	5	0	5	2	315	5	<40	3
1989	30	50	1	51	22	530	49	<40	3
1990	28	52	1	53	29	550	49	<40	3
1991	29	36	3	39	12	535	35	<40	3
1992	28	52	5	57	21	610	56	<40	3
1993	27	115	14	129	71	540	121	<40	3
1994	26	67	13	80	48	480	75	<40	3
1995	26	121	18	139	71	600	131	<40	3
1996	24	301	48	349	184	555	312	<40	3
1997	22	257	32	289	161	570	260	<40	3
1998	21	179	41	220	138	565	200	<40	3
1999	21	150	39	189	115	560	172	<40	3
2000	21	113	29	142	84	600	132	<40	3
2001	21	108	25	133	79	530	124	<40	3
2002	20	114	25	139	76	595	123	<40	3
2003	19	132	24	156	90	567	141	<40	3
2004	18	141	35	176	110	580	163	<40	3
2005	17	174	40	214	126	650	189	<40	3
2006	16	163	40	203	122	590	182	<40	3
2007	15	228	43	271	160	650	247	<40	3
2008	14	264	60	324	223	620	293	<40	3
2009	13	289	61	350	214	650	316	<40	3
2010	12	252	66	318	193	680	290	<40	3
2011	11	314	71	385	244	665	346	<40	3
2012	10	252	60	312	189	720	281	<40	3
2013	9	249	66	315	201	670	288	<40	3
2014	9	264	50	314	181	720	275	<40	3
2015	8	261	44	305	186	680	274	<40	3
2016	7	239	52	291	166	700	256	<40	3
2017	6	199	30	229	150	680	207	<40	3
2018	5	183	50	233	139	710	204	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







2.1 Duration of ARV treatment in the Province of BC, 1987-2023 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All		ent CD4 Median	Curr (n)	rent PVL Median	Current ARV Median
2019	4	220	41	261	176	665	232	<40	3
2020	3	182	53	235	165	740	209	<40	3
2021	2	193	35	228	134	600	200	<40	3
2022	1	267	54	321	233	620	298	<40	3
2023	0	49	12	61	46	545	55	<40	3
Total:		6239	1281	7520					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1151	620
MAY-2022	7477	763	1998	<40	1304	620
JUN-2022	7482	759	1839	<40	1200	630
JUL-2022	7495	754	1761	<40	1139	645
AUG-2022	7493	758	1990	<40	1225	620
SEP-2022	7443	771	1787	<40	1087	640
OCT-2022	7469	777	1849	<40	1161	640
NOV-2022	7502	783	1898	<40	1188	630
DEC-2022	7547	787	1607	<40	997	640
JAN-2023	7588	793	2052	<40	1294	650
FEB-2023	7534	807	1728	<40	979	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period) PVL and CD4 tests defined as tests done in the specified month









2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	775	334	60	<40	43	490
JUN-2022	778	317	61	<40	43	400
JUL-2022	781	297	61	<50	35	453
AUG-2022	803	275	59	78	48	550
SEP-2022	860	223	71	<40	53	460
OCT-2022	843	230	83	<40	61	500
NOV-2022	830	236	80	50	59	490
DEC-2022	792	267	57	<40	45	560
JAN-2023	750	322	62	<40	44	553
FEB-2023	800	253	66	<40	51	550

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month







Monthly Report

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14504
FEB-2022	7371	856	8	9	151	211	-61	14529
MAR-2022	7432	800	16	9	232	160	61	14558
APR-2022	7397	834	11	1	156	178	-35	14578
MAY-2022	7450	775	13	13	205	146	53	14602
JUN-2022	7457	778	11	15	178	170	7	14639
JUL-2022	7469	781	10	13	188	176	12	14678
AUG-2022	7469	803	15	17	169	171	0	14716
SEP-2022	7424	860	13	15	146	191	-45	14744
OCT-2022	7446	843	14	16	196	171	22	14779
NOV-2022	7483	830	9	17	209	177	37	14818
DEC-2022	7518	792	19	8	215	166	35	14845
JAN-2023	7560	750	20	10	194	142	42	14880
FEB-2023	7520	800	10	14	158	202	-40	14906

2.4 BC-CfE Enrolment

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report

2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6366	441	43	7493	8.58%	84.96%	5.89%	0.57%	100.00%
SEP-2022	663	6296	439	45	7443	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6310	439	41	7469	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6318	446	42	7502	9.28%	84.22%	5.95%	0.56%	100.00%
DEC-2022	709	6347	449	42	7547	9.39%	84.10%	5.95%	0.56%	100.00%
JAN-2023	721	6378	445	44	7588	9.50%	84.05%	5.86%	0.58%	100.00%
FEB-2023	735	6331	429	39	7534	9.76%	84.03%	5.69%	0.52%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lam	ivudir	e			aba	cavir			zidov	udine		te	nofovi	r <taf< th=""><th>-></th><th>te</th><th>nofovi</th><th>r <tdf< th=""><th>-></th><th>(</th><th>emtric</th><th>itabine</th><th>;</th></tdf<></th></taf<>	->	te	nofovi	r <tdf< th=""><th>-></th><th>(</th><th>emtric</th><th>itabine</th><th>;</th></tdf<>	->	(emtric	itabine	;
	Initial		All		Init	ial	All		Initi	al	All		Init	tial	All		Init	ial	All		Init	ial	All	
JAN-2022	3 209	6 306	64 42	2%	3	20%	2480	34%	0	0%	19	0%	12	80%	2922	40%	0	0%	1473	20%	12	80%	4262	58%
FEB-2022	6 249	% 30 ⁻	19 42	2%	3	12%	2410	33%	2	8%	19	0%	15	60%	2939	41%	4	16%	1395	19%	19	76%	4225	58%
MAR-2022	3 10	6 303	34 41	1%	2	7%	2406	33%	0	0%	19	0%	24	83%	3029	41%	2	7%	1350	18%	26	90%	4272	58%
APR-2022	4 209	% 30 ⁻	19 41	1%	3	15%	2366	33%	0	0%	19	0%	14	70%	3052	42%	2	10%	1313	18%	16	80%	4250	58%
MAY-2022	4 179	6 302	26 41	1%	3	13%	2354	32%	0	0%	18	0%	17	74%	3145	43%	2	9%	1282	17%	19	83%	4309	59%
JUN-2022	5 149	% 30 ⁻	15 41	1%	0	0%	2309	31%	0	0%	19	0%	29	81%	3199	44%	4	11%	1237	17%	31	86%	4320	59%
JUL-2022	4 10	6 300	07 41	1%	3	8%	2285	31%	0	0%	19	0%	27	69%	3229	44%	9	23%	1218	17%	35	90%	4343	59%
AUG-2022	5 149	6 299	92 41	1%	4	11%	2262	31%	0	0%	18	0%	29	78%	3271	45%	3	8%	1178	16%	32	86%	4353	59%
SEP-2022	4 14	6 29	53 40)%	3	11%	2196	30%	0	0%	17	0%	19	68%	3284	45%	5	18%	1173	16%	24	86%	4352	60%
OCT-2022	6 179	6 29	51 40)%	4	11%	2174	30%	0	0%	16	0%	29	83%	3350	46%	0	0%	1143	16%	29	83%	4388	60%
NOV-2022	7 189	6 294	48 40)%	5	13%	2158	29%	0	0%	15	0%	26	68%	3387	46%	6	16%	1136	15%	31	82%	4417	60%
DEC-2022	4 159	6 29	52 40)%	3	11%	2149	29%	1	4%	16	0%	18	67%	3447	47%	5	19%	1110	15%	23	85%	4447	60%
JAN-2023	6 179	6 29	73 40)%	1	3%	2149	29%	1	3%	16	0%	23	66%	3493	47%	8	23%	1098	15%	29	83%	4470	60%
FEB-2023	3 129	6 294	49 40)%	1	4%	2101	28%	0	0%	17	0%	20	77%	3508	47%	3	12%	1069	14%	23	88%	4454	60%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

[fo	samp	renavii			ataza	navir			daru	navir			lopir	navir			ritor	avir			tiprar	navir	
	Initia	al	All		Init	ial	All		Ini	itial	All		Init	ial	All		Initi	al	All		Initi	al	All	
JAN-2022	0	0%	1	0%	0	0%	476	29%	0	0%	1132	68%	0	0%	60	4%	0	0%	1	0%	0	0%	1	0%
FEB-2022	0	0%	1	0%	1	33%	447	28%	1	33%	1110	69%	1	33%	60	4%	0	0%	1	0%	0	0%	1	0%
MAR-2022	0	0%	1	0%	0	0%	430	27%	2	100%	1113	70%	0	0%	57	4%	0	0%	1	0%	0	0%	1	0%
APR-2022	0	0%	1	0%	0	0%	424	27%	0	0%	1085	69%	0	0%	56	4%	0	0%	1	0%	0	0%	1	0%
MAY-2022	0	0%	1	0%	1	33%	417	27%	2	67%	1080	70%	0	0%	53	3%	0	0%	1	0%	0	0%	1	0%
JUN-2022	0	0%	1	0%	0	0%	407	27%	1	100%	1056	70%	0	0%	52	3%	0	0%	1	0%	0	0%	1	0%
JUL-2022	0	0%	1	0%	0	0%	405	27%	1	100%	1039	70%	0	0%	50	3%	0	0%	1	0%	0	0%	1	0%
AUG-2022	0	0%	1	0%	0	0%	386	26%	1	100%	1028	70%	0	0%	45	3%	0	0%	1	0%	0	0%	1	0%
SEP-2022	0	0%	0	0%	0	0%	368	26%	2	100%	1010	71%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
OCT-2022	0	0%	0	0%	0	0%	355	25%	0	0%	1002	72%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
NOV-2022	0	0%	0	0%	0	0%	352	25%	6	100%	995	72%	0	0%	43	3%	0	0%	1	0%	0	0%	1	0%
DEC-2022	0	0%	0	0%	0	0%	341	24%	1	100%	1008	72%	0	0%	45	3%	0	0%	1	0%	0	0%	1	0%
JAN-2023	0	0%	0	0%	0	0%	339	25%	1	100%	995	72%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
FEB-2023	0	0%	0	0%	0	0%	321	24%	0	0%	956	73%	0	0%	43	3%	0	0%	1	0%	0	0%	1	0%

2.7 Number of Participants on Protease Inhibitor by INGREDIENT

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

		dora	virine			efav	irenz			etrav	ririne			nevira	apine			rilpiv	virine	
	Init	ial	All		Ini	tial	All		Initi	al	All		Init	tial	All		Init	ial	All	
JAN-2022	0	0%	103	9%	0	0%	328	30%	0	0%	130	12%	0	0%	317	29%	0	0%	235	21%
FEB-2022	0	0%	106	10%	0	0%	317	29%	0	0%	127	12%	0	0%	306	28%	1	100%	228	21%
MAR-2022	0	0%	113	11%	1	100%	303	28%	0	0%	132	12%	0	0%	301	28%	0	0%	222	21%
APR-2022	1	50%	124	12%	1	50%	301	28%	0	0%	130	12%	0	0%	297	28%	0	0%	223	21%
MAY-2022	0	0%	136	13%	0	0%	287	27%	0	0%	128	12%	0	0%	290	27%	1	100%	220	21%
JUN-2022	1	33%	149	14%	1	33%	284	27%	0	0%	122	12%	0	0%	285	27%	1	33%	211	20%
JUL-2022	0	0%	155	15%	1	33%	280	27%	0	0%	117	11%	0	0%	280	27%	2	67%	207	20%
AUG-2022	0	0%	157	15%	1	33%	275	27%	0	0%	119	12%	0	0%	274	27%	2	67%	204	20%
SEP-2022	0	0%	167	16%	3	100%	271	27%	0	0%	110	11%	0	0%	273	27%	0	0%	200	20%
OCT-2022	0	0%	173	17%	0	0%	261	26%	0	0%	105	10%	0	0%	269	27%	0	0%	196	20%
NOV-2022	1	33%	183	18%	2	67%	261	26%	0	0%	108	11%	0	0%	269	26%	0	0%	197	19%
DEC-2022	0	0%	186	19%	1	25%	254	25%	0	0%	107	11%	1	25%	262	26%	2	50%	195	19%
JAN-2023	3	43%	192	19%	4	57%	247	25%	0	0%	107	11%	0	0%	255	26%	0	0%	191	19%
FEB-2023	0	0%	203	21%	0	0%	250	25%	0	0%	98	10%	0	0%	249	25%	0	0%	190	19%

2.8 Number of Participants on Non-Nucleosides by INGREDIENT

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report

2.9	Number of Participants on Entry/Integrase Inhibitors by INGREDIENT
-----	--

		bicte	gravir			dolute	egravir			elvite	gravir			fostem	savir			mara	viroc			ralteg	gravir	
	Init	ial	All		Init	tial	All		Initi	al	All		Initi	al	All		Initi	al	All		Initi	al	All	
JAN-2022	11	73%	2421	43%	2	13%	2468	44%	1	7%	347	6%	0	0%	0	0%	0	0%	24	0%	1	7%	374	7%
FEB-2022	15	71%	2443	44%	6	29%	2437	44%	0	0%	331	6%	0	0%	0	0%	0	0%	21	0%	0	0%	369	7%
MAR-2022	23	85%	2536	45%	3	11%	2460	43%	1	4%	324	6%	0	0%	0	0%	0	0%	21	0%	0	0%	370	7%
APR-2022	14	74%	2574	45%	5	26%	2436	43%	0	0%	312	5%	0	0%	0	0%	0	0%	20	0%	0	0%	366	6%
MAY-2022	17	77%	2666	46%	5	23%	2455	43%	0	0%	309	5%	0	0%	0	0%	0	0%	22	0%	0	0%	360	6%
JUN-2022	29	85%	2710	47%	5	15%	2454	42%	0	0%	300	5%	0	0%	0	0%	0	0%	22	0%	0	0%	352	6%
JUL-2022	24	69%	2745	47%	7	20%	2452	42%	3	9%	297	5%	0	0%	0	0%	0	0%	22	0%	1	3%	342	6%
AUG-2022	26	76%	2790	48%	6	18%	2452	42%	1	3%	294	5%	0	0%	0	0%	1	3%	22	0%	1	3%	340	6%
SEP-2022	19	76%	2820	48%	6	24%	2433	42%	0	0%	281	5%	0	0%	0	0%	0	0%	21	0%	0	0%	323	6%
OCT-2022	28	80%	2889	49%	6	17%	2440	41%	1	3%	280	5%	0	0%	0	0%	0	0%	22	0%	0	0%	314	5%
NOV-2022	24	73%	2920	49%	8	24%	2462	41%	1	3%	276	5%	0	0%	1	0%	0	0%	22	0%	0	0%	309	5%
DEC-2022	16	70%	2975	50%	5	22%	2466	41%	1	4%	270	4%	0	0%	1	0%	0	0%	20	0%	1	4%	308	5%
JAN-2023	23	82%	3018	50%	5	18%	2494	41%	0	0%	269	4%	0	0%	1	0%	0	0%	21	0%	0	0%	303	5%
FEB-2023	20	77%	3046	50%	6	23%	2480	41%	0	0%	255	4%	0	0%	1	0%	0	0%	21	0%	0	0%	288	5%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY		sted PI (t)RTIs %		NNRTI (t)RTIs %	+ 2 N n	INSTI (t)RTIs %	-	s from lasses %	≥ 3 drug ≥ 3 c n	s from lasses %	n	Other %
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4610	61.52	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	691	9.28	4575	61.47	662	8.89	641	8.61	74	0.99
OCT-2022	789	10.56	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	773	10.24	663	8.78	4684	62.06	706	9.35	650	8.61	71	0.94
JAN-2023	752	9.91	665	8.76	4733	62.37	718	9.46	648	8.54	72	0.95
FEB-2023	717	9.52	666	8.84	4722	62.68	733	9.73	625	8.30	71	0.94

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month
 Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	14	2	2	4	1	5	279

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive) **Baseline CD4** is defined as most recent CD4 test before ARV start







2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Partcipants with PVL test, and never on ART	
JAN-2022	12306	3762	
FEB-2022	12329	3776	
MAR-2022	12358	3792	
APR-2022	12387	3817	
MAY-2022	12378	3806	
JUN-2022	12393	3808	
JUL-2022	12419	3817	
AUG-2022	12440	3829	
SEP-2022	12459	3838	
OCT-2022	12486	3859	
NOV-2022	12493	3848	
DEC-2022	12471	3831	
JAN-2023	12464	3818	
FEB-2023	12452	3801	

Definitions:

Patients with PVL test are defined as having at leat one PVL test within previous five years, and not reported deceased/moved Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month










Distribution of HIV/AIDS Drug Treatment Program Active Participants Feb-2023 3.1 N = 7534



ALTH CARE

How you want to be treated.

in HIV/AIDS


Ministry of

Health

BRITISH COLUMBIA

3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant Feb-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant Feb-2023










BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant Feb-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



Distribution of HIV/AIDS Drug Treatment Program Active Participant 3.5 Feb-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



CENTRE for **EXCELLENCE** in HIV/AIDS



Ministry of


Health

Drug definitions available in the back.

BRITISH COLUMBIA

HIV/AIDS Drug Treatment Program Monthly Report

3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant Feb-2023



NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Ago Croup	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST	Age Group 20-34	Allve		
KOOTENAY	35-49	*	*	*
	35-49 50+	*	*	*
	Total HSDA:	45	61	27
KOOTENAY	0-19	45	*	<u> </u>
BOUNDARY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	75	103	53
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	428	584	317
THOMPSON/CARIBOO/	0-19	+20	*	*
SHUSWAP	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	223	302	169
Total HA:		771	1050	566
			Ever	Currently
	Age Group	Alive	treated with ARVs	treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		771	1050	566
			Ever	Currently
Sex at Birth		Alive	treated with ARVs	treated with ARVs
Female		160	218	122
Male		611	832	444
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		566	56	660 <40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

Total HA:		771	566
	<5 years	129	104
	5 years or more	152	107
	10 years or more	490	355
	Treatment Duration	Alive	Currently treated with ARVs
Total HA:		771	566
	Total HSDA:	223	169
	<5 years	38	29
SHUSWAP	5 years or more	44	30
THOMPSON/CARIBOO/	10 years or more	141	110
	Total HSDA:	428	317
	<5 years	69	55
	5 years or more	82	60
OKANAGAN	10 years or more	277	202
	Total HSDA:	75	53
	<5 years	14	12
BOUNDARY	5 years or more	14	11
KOOTENAY	10 years or more	47	30
	Total HSDA:	45	27
	<5 years	8	8
KOOTENAY	5 years or more	12	6
EAST	10 years or more	25	13
HSDA	Duration	Alive	treated with ARVs
	Treatment		Currently

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	11	19
KOOTENAY BOUNDARY	78	137	23	47
OKANAGAN	239	1072	53	353
THOMPSON/CARIBOO/SHUSWAR	P 151	559	37	140
Total:	519	1838	124	559

HSDA of	# of Patients seeking Prescriber's care	
Patient Residency	out of HA	
EAST KOOTENAY	8	
KOOTENAY BOUNDARY	11	
OKANAGAN	58	
THOMPSON/CARIBOO/SHU	SWAP 43	
Total:	120	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months # of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
FRASER EAST	0-19	7	7	7	
	20-34	38	40	29	
	35-49	101	105	65	
	50+	258	359	190	
	Total HSDA:	404	511	291	
FRASER NORTH	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	1141	1543	865	
FRASER SOUTH	0-19	9	9	9	
	20-34	101	103	72	
	35-49	297	324	231	
	50+	624	949	510	
	Total HSDA:	1031	1385	822	
Total HA:		2576	3439	1978	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	17	17	17	
	20-34	266	271	184	
	35-49	758	815	580	
	50+	1535	2336	1197	
Total HA:		2576	3439	1978	
			Ever	Currently	
Sex at Birth		Alive	treated with ARVs	treated with ARVs	
Female		626	799	468	
Male		1950	2640	1510	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med P	VL
Total HA:		1978	53	650 <40)

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
FRASER EAST	10 years or more	264	191
	5 years or more	71	43
	<5 years	69	57
	Total HSDA:	404	291
FRASER NORTH	10 years or more	713	514
	5 years or more	237	188
	<5 years	191	163
	Total HSDA:	1141	865
FRASER SOUTH	10 years or more	645	498
	5 years or more	215	172
	<5 years	171	152
	Total HSDA:	1031	822
Total HA:	1	2576	1978
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	1622	1203
	5 years or more	523	403
	<5 years	431	372
Total HA:	-	2576	1978

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	148	535	34	65
FRASER NORTH	260	1611	39	219
FRASER SOUTH	227	1785	49	486
Total:	635	3931	122	770

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA	
FRASER EAST	202	
FRASER NORTH	713	
FRASER SOUTH	463	
Total:	1378	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

			Ever	Currently
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs
NORTH SHORE/	0-19	*	*	*
COAST GARIBALDI	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	352	521	273
RICHMOND	20-34	32	33	20
	35-49	52	53	42
	50+	117	172	94
	Total HSDA:	201	258	156
VANCOUVER	0-19	12	12	10
	20-34	444	458	302
	35-49	1233	1374	865
	50+	2974	5294	2122
	Total HSDA:	4663	7138	3299
Total HA:		5216	7917	3728
			Ever	Currently
	Age Group	Alive	treated with ARVs	treated with ARVs
	0-19	13	13	11
	20-34	503	518	339
	35-49	1362	1512	961
	50+	3338	5874	2417
Total HA:		5216	7917	3728
			Ever	Currently
Sex at Birth		Alive	treated with ARVs	treated with ARVs
Female		601	964	443
Male		4613	6951	3285
Unknown		2	2	0
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		3728	55	650 <40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/	10 years or more	238	185
COAST GARIBALDI	5 years or more	54	44
	<5 years	60	44
	Total HSDA:	352	273
RICHMOND	10 years or more	122	91
	5 years or more	36	25
	<5 years	43	40
	Total HSDA:	201	156
VANCOUVER	10 years or more	*	2221
	5 years or more	*	605
	<5 years	*	473
	Never on ART	*	0
	Total HSDA:	4663	3299
Total HA:		5216	3728
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	*	2497
	5 years or more	*	674
	<5 years	*	557
	Never on ART	*	0
Total HA:		5216	3728

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBAL	DI 187	417	40	60
RICHMOND	45	311	9	93
VANCOUVER	679	11520	212	5418
Total:	911	12248	261	5571

HSDA of seek Patient Residency	# of Patients ing Prescriber's care out of HA	
NORTH SHORE/COAST GARIBALD) *	
RICHMOND	*	
VANCOUVER	*	
Total:	75	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months **# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

			Ever	Currently	
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs	
CENTRAL	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	361	522	290	
NORTH	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	126	177	102	
SOUTH	20-34	71	77	48	
VANCOUVER	35-49	191	217	145	
ISLAND	50+	538	858	407	
	Total HSDA:	800	1152	600	
Total HA:		1287	1851	992	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
Total HA:		1287	1851	992	
			Ever	Currently	
Sex at Birth		Alive	treated with ARVs	treated with ARVs	
Female		221	320	169	
Male		1066	1531	823	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL	
Total HA:		992	56	590 <40	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)







4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
CENTRAL	10 years or more	218	178
VANCOUVER	5 years or more	79	57
ISLAND	<5 years	64	55
	Total HSDA:	361	290
NORTH	10 years or more	86	71
VANCOUVER	5 years or more	26	19
ISLAND	<5 years	14	12
	Total HSDA:	126	102
SOUTH	10 years or more	491	351
VANCOUVER	5 years or more	161	128
ISLAND	<5 years	148	121
	Total HSDA:	800	600
Total HA:		1287	992
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	795	600
	5 years or more	266	204
	<5 years	226	188
Total HA:		1287	992

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.12 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	923	73	163
NORTH VANCOUVER ISLAND	157	280	37	68
SOUTH VANCOUVER ISLAND	222	1934	34	587
Total:	582	3137	144	818

HSDA of		# of Patients g Prescriber's care
Patient Residency		out of HA
CENTRAL VANCOUVER	R ISLAND	116
NORTH VANCOUVER I	SLAND	43
SOUTH VANCOUVER I	SLAND	130
Total:		289

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

			Ever	Currently
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs
NORTH EAST	20-34	8	8	5
	35-49	15	18	11
	50+	28	36	15
	Total HSDA:	51	62	31
NORTH WEST	20-34	*	6	*
	35-49	*	38	*
	50+	*	75	*
	Total HSDA:	71	119	51
NORTHERN INTERIOR	0-19	6	6	*
	20-34	19	19	*
	35-49	57	74	*
	50+	115	196	*
	Total HSDA:	197	295	147
Total HA:		319	476	229
			Ever	Currently
			Evei	Currentity
	Age Group	Alive	treated with ARVs	treated with ARVs
	Age Group 0-19	Alive 6		
	• .		treated with ARVs	treated with ARVs
	0-19	6	treated with ARVs 6	treated with ARVs
	0-19 20-34	6 31	treated with ARVs 6 33	treated with ARVs * *
Total HA:	0-19 20-34 35-49	6 31 96	treated with ARVs 6 33 130	treated with ARVs * * * *
Total HA:	0-19 20-34 35-49	6 31 96 186	treated with ARVs 6 33 130 307	treated with ARVs * * * * 229
Total HA: Sex at Birth	0-19 20-34 35-49	6 31 96 186	treated with ARVs 6 33 130 307 476	treated with ARVs * * * * *
	0-19 20-34 35-49	6 31 96 186 319	treated with ARVs 6 33 130 307 476 Ever	treated with ARVs * * * 229 Currently
Sex at Birth	0-19 20-34 35-49	6 31 96 186 319 Alive	treated with ARVs 6 33 130 307 476 Ever treated with ARVs	treated with ARVs * * * 229 Currently treated with ARVs
Sex at Birth Female	0-19 20-34 35-49 50+	6 31 96 186 319 Alive 113	treated with ARVs 6 33 130 307 476 Ever treated with ARVs 174	treated with ARVs * * 229 Currently treated with ARVs 76

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)









4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	6	*
	<5 years	15	*
	Total HSDA:	51	31
NORTH WEST	10 years or more	51	35
	5 years or more	10	9
	<5 years	10	7
	Total HSDA:	71	51
NORTHERN INTERIOR	10 years or more	104	79
	5 years or more	60	41
	<5 years	33	27
	Total HSDA:	197	147
Total HA:		319	229
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	185	129
	5 years or more	76	54
	<5 years	58	46
Total HA:	-	319	229

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.15 Distribution of ARV Prescribers in BC-CfE Registries NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	40	60	6	8
NORTH WEST	85	173	15	36
NORTHERN INTERIOR	124	500	22	193
Total:	249	733	43	237

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA	
NORTH EAST	5	
NORTH WEST	19	
NORTHERN INTERIOR	12	
Total:	36	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





НА	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
	-	-		
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	32	52	21
	THOMPSON/CARIBOO/SHUSWAP	26	50	19
	Total HA:	70	123	50
FRASER	FRASER EAST	35	50	28
	FRASER NORTH	44	86	35
	FRASER SOUTH	82	118	62
	Total HA:	161	254	125
VANCOUVER	NORTH SHORE/COAST GARIBALDI	25	51	21
COASTAL	RICHMOND	6	11	5
	VANCOUVER	461	908	375
	Total HA:	492	970	401
VANCOUVER	CENTRAL VANCOUVER ISLAND	47	81	38
ISLAND	NORTH VANCOUVER ISLAND	16	30	11
	SOUTH VANCOUVER ISLAND	49	96	40
	Total HA:	112	207	89
NORTHERN	NORTH EAST	9	13	5
	NORTH WEST	31	67	22
	NORTHERN INTERIOR	68	115	53
	Total HA:	108	195	80
Total:		943	1749	745

4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs	
Male	599	1123	468	
Female	344	626	277	
Currently treated with ARVs	# of patients	Med Age	Med CD4 Med PVL	
Total:	745	53	530 <40	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.









Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It its currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.







Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are preactivated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.





